Analysis of vanin-1 upregulation and lipid accumulation in hepatocytes in response to a high-fat diet and free fatty acids

Journal of Clinical Biochemistry and Nutrition

Volumn 51, Issue 3, 2012, Pages 163-169

  Motomura, Wataru ^a   Yoshizaki, Takayuki ^b   Takahashi, Nobuhiko ^a   Kumei, Shima ^a   Mizukami, Yusuke ^a   Jang, Seong Jae ^a   Kohgo, Yutaka ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Fatty acids; Lipid droplet; Nonalcoholic fatty liver disease; Vanin 1

Indexed keywords

ENZYME; FATTY ACID; LIPID; MESSENGER RNA; OLEIC ACID; UNCLASSIFIED DRUG; VANIN 1;

ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIPID DIET; LIPID STORAGE; LIVER CELL; MALE; MOUSE; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; UPREGULATION;

MUS;

EID: 84868605794     PISSN: 09120009     EISSN: None     Source Type: Journal    
DOI: 10.3164/jcbn.12-06     Document Type: Article

References (38)

1. Vega GL. Obesity and the metabolic syndrome. Minerva Endocrinol 2004; 29: 47-54.
2. Fujimoto Y, Onoduka J, Homma KJ, et al. Long-chain fatty acids induce lipid droplet formation in a cultured human hepatocyte in a manner dependent of Acyl-CoA synthetase. Biol Pharm Bull 2006; 29: 2174-2180. (Pubitemid 44690938)
3. Argo C, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 2009; 51: 371-379.
4. Lewis JR, Mohanty SR. Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci 2010; 55: 560-578.
5. Day CP, James OF. Steatohepatitis: a tale of two "hits" ? Gastroenterology 1998; 114: 842-845.
6. Youssef WI, McCullough AJ. Steatohepatitis in obese individuals. Best Pract Res Clin Gastroenterol 2002; 16: 733-747.
7. Yu S, Viswakarma N, Batra SK, Samabasiva Rao M, Reddy JK. Identification of promethin and PGLP as two novel up-regulated genes in PPARgamma1-induced adipogenic mouse liver. Biochimie 2004; 86: 743-761. (Pubitemid 39602753)
8. Sato W, Horie Y, Kataoka E, et al. Hepatic gene expression in hepatocyte-specific Pten deficient mice showing steatohepatitis without ethanol challenge. Hepatol Res 2006; 34: 256-265.
9. Guillén N, Navarro MA, Arnal C, et al. Microarray analysis of hepatic gene expression identifies new genes involved in steatotic liver. Physiological Genomics 2009; 37: 187-198.
10. Aurrand-Lions M, Galland F, Bazin H, Zakharyev VM, Imhof BA, Naquet P. Vanin-1, a novel GPI-linked perivascular molecule involved in thymus homing. Immunity 1996; 5: 391-405. (Pubitemid 26423468)
11. Pitari G, Malergue F, Martin F, et al. Pantetheinase activity of membrane-bound Vanin-1: lack of free cysteamine in tissues of Vanin-1 deficient mice. FEBS Lett 2000; 483: 149-154.
12. -/- mice exhibit a glutathione-mediated tissue resistance to oxidative stress. Mol Cell Biol 2004; 24: 7214-7224.
13. Berruyer C, Pouyet L, Millet V, et al. Vanin-1 licenses inflammatory mediator production by gut epithelial cells and controls colitis by antagonizing peroxisome proliferator-activated receptor gamma activity. J Exp Med 2006; 203: 2817-2827. (Pubitemid 46026160)
14. -/- mice show decreased NSAID- and Schistosoma-induced intestinal inflammation associated with higher glutathione stores. J Clin Invest 2004; 113: 591-597.
15. Pouyet L, Roisin-Bouffay C, Clement A, et al. Epithelial vanin-1 controls inflammation-driven carcinogenesis in the colitis-associated colon cancer model. Inflamm Bowel Dis 2010; 16: 96-104.
16. Roisin-Bouffay C, Castellano R, Valéro R, Chasson L, Galland F, Naquet P. Mouse vanin-1 is cytoprotective for islet beta cells and regulates the development of type 1 diabetes. Diabetologia 2008; 51: 1192-1201.
17. Terayama R, Bando Y, Murakami K, Kato K, Kishibe M, Yoshida S. Neuropsin promotes oligodendrocyte death, demyelination and axonal degeneration after spinal cord injury. Neuroscience 2007; 148: 175-187. (Pubitemid 47211613)
18. Yoshizaki T, Motomura W, Tanno S, Kumei S, Yoshizaki Y, Okumura T. Thiazolidinediones enhance vascular endothelial growth factor expression and induce cell growth inhibition in non-small-cell lung cancer cells. J Exp Clin Cancer Res 2010; 29: 22.
19. Kumei S, Motomura W, Yoshizaki T, Takakusaki K, Okumura T. Troglitazone increases expression of E-cadherin and claudin 4 in human pancreatic cancer cells. Biochem Biophys Res Commun 2009; 380: 614-619.
20. Inoue M, Ohtake T, Motomura W, et al. Increased expression of PPARgamma in high fat diet-induced liver steatosis in mice. Biochem Biophys Res Commun 2005; 336: 215-222. (Pubitemid 41253423)
21. Diehl AM. Lessons from animal models of NASH. Hepatol Res 2005; 33: 138-144. (Pubitemid 41799792)
22. Ockerman HW. Source book for food scientists. Connecticut: AVI Publishing Company, 1978; 151-152.
23. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004; 114: 147-152. (Pubitemid 39071617)
24. Day CP. From fat to inflammation. Gastroenterology 2006; 130: 207-210. (Pubitemid 43049850)
25. Lalor PF, Faint J, Aarbodem Y, Hubscher SG, Adams DH. The role of cytokines and chemokines in the development of steatohepatitis. Semin Liver Dis 2007; 27: 173-193. (Pubitemid 46871663)
26. Nitto T, Inoue T, Node K. Alternative spliced variants in the pantetheinase family of genes expressed in human neutrophils. Gene 2008; 426: 57-64.
27. Slyshenkov VS, Dymkowska D, Wojtczak L. Pantothenic acid and pantothenol increase biosynthesis of glutathione by boosting cell energetics. FEBS Lett 2004; 569: 169-172. (Pubitemid 38844612)
28. Pyper SR, Viswakarma N, Yu S, Reddy JK. PPARalpha: energy combustion, hypolipidemia, inflammation and cancer. Nucl Recept Signal 2010; 8: e002.
29. Fruchart JC. Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease. Atherosclerosis 2009; 205: 1-8.
30. Yoon M. The role of PPARalpha in lipid metabolism and obesity: focusing on the effects of estrogen on PPARalpha actions. Pharmacol Res 2009; 60: 151-159.
31. Motomura W, Inoue M, Ohtake T, et al. Up-regulation of ADRP in fatty liver in human and liver steatosis in mice fed with high fat diet. Biochem Biophys Res Commun 2006; 340: 1111-1118. (Pubitemid 43083393)
32. Mak KM, Ren C, Ponomarenko A, Cao Q, Lieber CS. Adipose differentiation-related protein is a reliable lipid droplet marker in alcoholic fatty liver of rats. Alcohol Clin Exp Res 2008; 32: 683-689. (Pubitemid 351430433)
33. Yamazaki K, Kuromitsu J, Tanaka I. Microarray analysis of gene expression changes in mouse liver induced by peroxisome proliferator-activated receptor alpha agonists. Biochem Biophys Res Commun 2002; 290: 1114-1122. (Pubitemid 34687479)
34. Wong JS, Gill SS. Gene expression changes induced in mouse liver by di(2-ethylhexyl) phthalate. Toxicol Appl Pharmacol 2002; 185: 180-196. (Pubitemid 36062792)
35. Moffit JS, Koza-Taylor PH, Holland RD, et al. Differential gene expression in mouse liver associated with the hepatoprotective effect of clofibrate. Toxicol Appl Pharmacol 2007; 222: 169-179. (Pubitemid 47094866)
36. Rakhshandehroo M, Knoch B, Müller M, Kersten S. Peroxisome proliferator-activated receptor alpha target genes. PPAR Research 2010.
37. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk-factors. Hepatology 1990; 12: 1106-1110.
38. Serviddio G, Sastre J, Bellanti F, Viña J, Vendemiale G, Altomare E. Mitochondrial involvement in non-alcoholic steatohepatitis. Mol Aspects Med 2008; 29: 22-35. (Pubitemid 351312221)